Compare TransMedics Group Inc (TMDX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $211.86 (market cap $39.88B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 13× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| TMDX | TTWO | |
|---|---|---|
Market Cap | $3.06B | $39.88B |
Sector | Technology | Media |
52-Week High | $150.42 | $262.29 |
52-Week Low | $61.99 | $189.69 |
Enterprise Value | $3.46B | $41.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Take-Two Interactive trades at $213.29, down 0.65% amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -4.79% net margin and -$4.48B net loss for 2025, though recent earnings beats and GTA 6's November launch anticipation provide catalysts. Cash flow improved to $457M net inflow in 2025 from prior deficits, while debt-to-asset ratio rose to 39.87%.
Outlook hinges on GTA 6's execution, with 79% analyst buy ratings and $302.60 price target suggesting 42% upside. Risks include high valuation multiples (P/S 5.91, EV/EBITDA 32.78) and reliance on single-title success. Near-term volatility may persist pending Q3 earnings and preorder trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
